In this issue:
- Surgery without adjuvant RT: adequate treatment for perineural BCCs
- TILs vs. ipilimumab in advanced melanoma
- Rate and characteristics of incompletely excised cutaneous SCC
- Lenvatinib + pembrolizumab for progressive melanoma on anti-PD1/PD-L1 therapy
- Melanoma in children and adolescents
- Dabrafenib + trametinib vs. nivolumab + ipilimumab for advanced BRAF-mutated melanoma
- External validation of SUNTRAC in solid organ transplant recipients
- Ipilimumab + nivolumab and encorafenib + binimetinib sequencing for untreated BRAF-mutated metastatic melanoma
- Fewer melanoma cases with regular vitamin D supplement use
- Adjuvant nivolumab ± ipilimumab in resected stage IIIB-D or stage IV melanoma
Please login below to download this issue (PDF)